Faslodex indicated for treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with hormonal therapy, or with disease relapse/progression on or after adjuvant endocrine therapy
Faslodex, in combination with the preparation palbociclib, is intended for women with advanced or metastatic estrogen receptor-positive and HER2-negative breast cancer, whose disease has progressed after receiving prior hormonal treatment for this ailment. When used in combination with palbociclib (Ibrance), please read the palbociclib (Ibrance) patient package insert as well.
Faslodex belongs to the group of medicines that block the activity of estrogen.
Ask your Oncologist how to use Faslodex if you are not sure.
The dosage and duration of Faslodex treatment will be determined by the doctor only.
Read the patient leaflet guide which is enclosed to each package.